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Abstract 
Background: Since the advent of HAART, there is a significant reduction in opportunistic Infections (OIs), morbidity, 
mortality and HIV transmission. However, the low antiretroviral Therapy (ART) coverage in resource-limited 
countries (42%) and the presence of globally 500-800 thousand patients on first-line having to required switch to 
second-line drugs in 2010 are some concerns. Other challenges related to HAART include: lifelong therapy, failed 
treatment response, optimal time to start treatment and switching regimens, drug interaction, toxicity, cardiovascular 
risks, drug resistance, lost to follow-up, immune reconstitution inflammatory syndrome (IRIS), early mortality, and 
lack of restoration of solid immunity against HIV. To achieve the goals of ART, national ART programmes focus on 
the vital patient monitoring systems including clinical, immunologic, virologic, adherence, lost to follow-up and 
mortality.  
Objectives: This review is aimed at addressing the profile of immunovirological responses to HAART and the factors 
associated with, with a special emphasis on the drawbacks of immunologic assessment to diagnose virologic failures. 
Main findings: WHO recommends clinical and immunological assessments as surrogates of plasma viral load (VL) to 
identify first-line treatment failures in resource-poor settings. However, immunological tools have poor sensitivity (20-
30%) and specificity (86-90%) to identify virologic failures that may lead to continue with failed regimen or to 
unnecessary switch of regimen which could result in a more complex profile of resistance. There are three main types 
of immunovirologic responders in clinical practice: concordant responders (40-60%), concordant non-responders (12-
27.3%), and discordant responders that include lack of CD4+ increases despite viral suppression (7-48%), and optimal 
CD4+ responses in the absence of viral suppression (5-23.8%), whereby the risk of morbidity and mortality is higher 
in the concordant non-responders and discordant responders. 
Conclusions: ART benefits a substantial number of HIV patients even in resource-poor settings. Since clinico-
immunological assessments have lower performance in diagnosing virologic failures, moving towards the availability 
of VL testing to confirm treatment failures, if not pre-HAART resistance testing, is a logical and timely approach for 
resource limited countries like Ethiopia where the long-term effect of the roll-out ART is not well investigated. 
However, the high cost and technical demand of VL testing, lack of experience of health professionals, weak 
infrastructure and health care system, the unavailability and high costs of second-line drugs could be the major 
challenges during expansion of VL testing. Moreover, longitudinal studies on long-term effects of HAART, and 
surveys focused on transmitted or acquired HIV drug resistance, and Early Warning Indicators are highly pertinent.  
[Ethiop. J. Health Dev.  2011;25(1):61-70] 
 
Introduction 
HIV/AIDS remains to be a global challenge since its 
discovery (1).  At the end of 2008, 33.4 million people 
were living with HIV, 2.7 million newly infected, and 2 
million deaths occurred due to HIV/AIDS worldwide (2).  
In Ethiopia, HIV prevalence of the adult population in 
2007 is estimated to be 2.1% (Urban 7.7%, Rural 0.9 %), 
and the number of people living with HIV is 977,394, 
including 64,813 children (3). 
 
Despite the absence of curative therapy for HIV/AIDS, 
highly active antiretroviral therapy (HAART) reduces 
OIs, HIV transmission, morbidity and mortality at global 
level (4, 5). Mean survival of those on HAART is 
estimated to be 13 years (6), although the high rates of 
deaths among lost to follow-ups should be considered for 
accurate estimate of survival (7). Moreover, since 
outcome of HAART at population level depends on the 
time of starting ART, uptake, adherence, pre-treatment 
and co-infections, survival following HAART might not 
be uniform in all HIV infected groups (8,9). 
 
Since the launching of “3 by 5” global initiative (10), > 
4.7 million people were on ART worldwide at the end of 
2008, although only 42% of the 9.5 million people in 
need of ART had an access in the resource limited 
countries (5).  In Ethiopia, where 3880 patients were 
getting free ART in three sites before the start of free 
ART in 2005,  >167,000 (~53%) of the adults requiring 
ART were getting the service in 517 health facilities as of 
October 2009 (11). Of those on ART in Ethiopia, 99% 
were on first line regimens with a retention rate of 74% 
(11), while retention rate in other African countries was 
75% and 67% at 12 and at 24 months, respectively (5). 
With all the success stories of HAART, there are 
challenges which could compromise the goals of ART 
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including failed/incomplete treatment responses (12), 
drug interaction and toxicity (13), drug resistance (14), 
lost to follow-up (5), and early mortality (15). Moreover, 
the presence of 500-800 thousand patients that require 
switching to second-line drugs in 2010 (5), and where 
this number could increase gradually with the expansion 
of ART services, indicates another challenge in terms of 
availability and increment of cost of the second-line 
therapy per patient (16). 
 
In summary, whereas the positive impact of ART is 
remarkable, in view of the patient monitoring system in 
resource-poor countries which is exclusively dependent 
on clinico-immunological methods, which lacks 
sensitivity/specificity to detect virological failures, 
accurate diagnosis and management of treatment failures 
could be a major challenge in the era of rapid ART 
expansion (17). The focus of the current review is 
therefore to highlight the profile of immunologic and 
virologic responses to HAART and the risk factors 
associated with treatment failures, with special emphasis 




This review comprises published articles in Ethiopia, in 
developing and the developed world which are related to 
HIV/AIDS infection, ART and the treatment outcomes as 
measured by immunological and virologic responses with 
special emphasis on the limitations of the immunological 
based monitoring of patients on ART. The review 
process was done through a desk review and online 




Monitoring of treatment responses in patients on 
HAART 
Although, the primary goal of HAART is to suppress 
plasma HIV-1 RNA level (viral load, VL) below the 
level of detection within three to six months of starting 
therapy and to maintain it for the rest of the patient’s life 
(18), there are other important goals of HARRT 
including restoring and preserveing immunologic 
function, reduceing HIV-related morbidity and mortality, 
improving quality of life and reducing vertical 
transmission (17). 
 
Since the discovery of Zidovudine (ZDV) in 1987 (19), 
more than 30 ARV drugs have been made available (20). 
Although it varies in different guidelines, according to 
WHO (21), first-line ART includes at least two 
nucleoside reverse transcriptase inhibitors (NRTIs) and 
one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) analog; while second-line ART includes two 
NRTIs boosted with protease inhibitors, preferably 
Ritonavir. The preferred first line regimens in Ethiopia 
includes Tenofovir (TDF) + Emtricitabine (FTC) + 
Efavirenz (EFV); ZDV+ Lamivudine (3TC)+ EFV; or 
ZDV+3TC+ Nevirapine (NVP) (21). 
 
Although, it varies in different settings, ART should be 
started when CD4+ count is 201-350, or <= 200/µl for 
developed and resource-poor settings, respectively (21). 
However, given the observed lower morbidity, mortality 
and fewer adverse events associated with the initiation of 
HAART at higher CD4 cell counts (23, 24), WHO 
recommends CD4+ count <= 350 cells/µl to initiate ART 
as a universal guideline (5). 
 
Times of initiating, replacing and stopping therapy are 
the most critical questions during ART (21). Based on 
the basics that progression of HIV infection is affected by 
the synergetic effect of immunological and virological 
along with host factors (race, genetics, age, gender, mode 
of transmission, co-infections, nutrition, pregnancy, 
psychosocial factors) (25), CD4+ count and VL 
measurements are golden prognostic biomarkers of 
HIV/AIDS disease progression (26). In settings where 
measurements of CD4+ count and VL level are limited,  
total lymphocyte count, hemoglobin (Hgb) and body 
mass index (BMI) are recommended as simple markers 
for disease progression (25, 27). 
 
Therefore, taking resource constraints into account, and 
that virological failures precede immunological failures, 
then comes clinical failure, WHO guidelines recommend 
clinical and immunological (CD4+ count) assessments as 
surrogates for VL to monitor patients on ART in resource 
limited settings, unlike to that in high income countries 
where VL is done three to four times a year (21). 
However, the sequential nature of treatment failure which 
is not strongly evidence based and may take years to 
happen is the major drawback of clinicoimmunological 
assessment based patient monitoring (17).  Evidence 
from models showed an average of five years from the 
first evidence of virological failure until 50% of patients 
progress to WHO stage III (3). Likewise, CD4+ counts 
correlate with the level of VL at group level but not at 
individual level (28). Thus, immunologic markers have 
poor sensitivity (20%-33%), specificity (86%-90%), with 
21% and 91%  positive and negative predictive values, 
respectively, to identify virologic failures which could 
lead to continue to treat patients with failed regimen or to 
unnecessary switch of regimens (29, 30). Thus higher 
morbidity, mortality and more complex profile of 
resistance were observed in settings where virologic 
assessment is not available (31). 
 
Definitions of ART failures 
The criteria to define ART failures are not uniform. 
According to WHO (21), there are three definitions: 
clinical failure when there is a recurrent WHO stage 4; 
immunologic failure when CD4 falls to below the pre-
therapy baseline, or below 50% of the on- peak value, or 
is persistently < 100 cells/mm; virologic failure when 
plasma VL >10000 copies/ml; Virologic success when 
VL is < 400 or 50 copies/ml (depending on the type of 
the assay) after six months of treatment (21). According 
to a recent WHO guideline, which recommends VL to be 
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done every six months, treatment failure is defined as 
persistent VL > 5000 copies/ml (5). Although not well 
defined, VL cut-off > 10000 copies/ml to define 
treatment failures is linked with subsequent decline in 
CD4+ cell count (32) and clinical progression (33). 
 
Others define immunologic failure as an increase of 
CD4+ cells/ul < 50 at 6-12 months (34); < 100 at 12-24 
months (35, 36), or < 500 at 4-5 years (37)  irrespective 
of viral suppression. Virologic failure was defined as a 
primary failure where VL does not decrease to < 50 
copies/ml on two different occasions after six months on 
ART; and secondary failure (viral rebound) where there 
is VL >50 copies/ml confirmed (21). 
 
Putting together, the variation in defining the cut-off 
values of treatment failures indicates the need of research 
and programmatic data to better understand the profile of 
immunovirological responses to HAART, which might 
differ in different countries. 
 
The profile of immunologic and virologic responses to 
HAART 
Immunologic responses (CD4+ recovery) 
Without therapy, the average decline rate of CD4 cells/µl 
("CD4 slope") is estimated to be 50 cells per year, and 
the average VL level ranges from 30,000 to 50,000 
copies/ml (26). CD4+ recovery following HAART, 
which is due to redistribution of the cells from tissues, 
regeneration of naïve T cells, or due to the reduction of 
immune activation mediated cell death (apoptosis) (37), 
occurs as a two phase process: In the first phase of  two 
months on ART, rapid increase of CD4+ cells occurs; 
and in the second phase of the third month and onwards 
on ART, CD4+ count increase slows down but persists 
over time (38). Overall, the long-term shape of CD4+ 
count after HAART depends on the baseline CD4+ 
count, control of viral replication overtime, the stage of 
the disease at baseline, duration on treatment (39, 40), as 
well as on baseline patient factors including higher HIV 
RNA level, co-morbidities, presence of drug resistant 
viruses, sub-optimal pharmacokinetics, and potency of 
the ARV regimen (17). The time required to reach to 
normal value of CD4+ counts ranges from two to eight 
years (24, 41). 
 
Immunological failure and the risk factors 
Complete immune recovery following HAART is not 
observed in any of the patients. Absent or modest 
improvements in CD4+ counts did occur in 5–27% of the 
patients on HAART that achieved plasma HIV-1 RNA 
suppression (42,43,44) which has clinical implications. 
Higher relative risk of progression to AIDS; and AIDS 
and non-AIDS related mortalities were reported among 
discordant responders as compared to those virologic and 
immunologic concordant responders (45). Whereas there 
is no clear understanding on how to assess immunologic 
failures with regard to time after HAART, questions such 
as the clinical risks and the possible treatment for 
immunological failures would be a concern for the health 
care workers in the ART clinic (46). 
 
Risk factors for  failure or incomplete immune recovery 
includ the degree of CD4+ decline before and at the 
initiation of the treatment (the steeper the decline the 
steeper the rise), the rate of decline in viral-load (47), old 
age (17, 47), co-infection (e.g. HCV, HIV-2, HTLV-1, 
HTLV-2), medications (ZDV, TDF+DDI), and persistent 
immune activation (17).  However, others have reported 
no difference in immunological response related to 
baseline viral load, HIV risk factor, sex, HCV co-
infection and HAART regimen (24). Several 
explanations have been given about the mechanisms by 
which inadequate immune CD4+ recovery occurred in 
response to HAART. These included, myelosuppressive 
effects of ARV drugs (e.g. ZDV) (48), thymic involution 
related to old age (49), and abnormal cell death 
(apoptosis) due to higher immune activation related to 
higher background risk of endemic infections (50). 
 
Virologic responses 
VL level is an excellent indicator of the degree of viral 
replication in the immune system, progression to AIDS, 
morbidity, mortality, and HIV transmission. VL level 
predicts also treatment success/failure faster than CD4+ 
counts and also resolves discordant clinico-
immunological responses, so that it is an important tool 
to protect 1st and 2nd line regimens from unnecessary 
switch whereby resistance risk, is reduce because of   all 
these factors, therefore, VL measurement has been 
considered as a golden standard to monitor patients on 
ART (51). However, whereas CD4+ level which 
measures the strength of the immune system is the best 
biomarker of when to start treatment (5), VL test is less 
necessary before initiating ART as it rarely informs when 
to start ART (21). 
 
Even though not always true, the minimum change in VL 
after treatment to be considered statistically significant (2 
standard deviations) is a threefold or a 0.5 log10 copies/ml 
change (52). Virologic response has been reported 
therefore to decrease at week 72 and disappeared after 96 
weeks of treatment (53). It has been observed also that 
75-90.7% of treatment-naïve patients reached 
undetectable viral load by 12 months on ART, while it 
was reduced to 72% after 24 months (53). The proportion 
of treatment  naïve patients with viral rebound was 9.4% 
after one year, and 20.1-20.6 % after 2 years, while it was 
35·7–40·1% after 2 years of pretreated patients (54,55). 
 
Virological failure and the risk factors  
The risk factors for virological failure includes sex 
(although reports are controversial) (19, 56), old age, 
poor adherence, previous exposure to ART, lower base 
line CD4+ count, OIs, TB after ART, persistent lower 
VL, insufficient CD4+ cell gain, clinical symptoms, 
lower weight than baseline, and emergence of drug 
resistant viruses (57,58). Digestive symptoms and poor 
adherence to ART were also reported as risk factors for 
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low ARV plasma concentrations (59), which in turn 
results in sub-optimal virlogical responses. 
Discordant/Concordant immunovirological responses 
Besides the independent immunologic and virologic 
failures (12), concordant/discordant responses are 
another challenge during ART. Although the frequency 
of concordant/discordant immunovirologic responders 
depends on the definition (cut-off values) of 
immunologic and virologic responses, there are three 
immunovirological responders in clinical practices: 1) 
Concordant responders (VL+/CD4+) (40-60%), 2) 
Concordant non-responders (VL-/CD4-) (12-27.3%), and  
3) discordant responders which is sub divided as 
immunological non-responders (lack of CD4 increases 
despite viral suppression (VL+ /CD4-), (7%-48%), and 
immunological responders (good CD4+ responses in the 
absence of viral suppression, VL-/CD4+) (5%-18%) (15, 
51, 59, 61, 62). 
 
Whereas discordant results complicate the interaction 
between virological and CD4+ count response (61), and 
cause more challenges to the health care providers during 
patient management and monitoring (51), higher risk of 
clinical progression and mortality was observed in 
discordant responders as compared to complete response 
(62,63). 
 
The risk factors for discordant/concordant ART 
responses 
The mechanisms of discordant response (VL+/CD4- , VL-
/CD4+) are not fully understood (36). Among the risk 
factors for VL+/CD4- were lower baseline CD4+ count 
(50-100/µl), higher baseline VL (100,000 copies/ml), 
HAART composed of three NRTIs, the use of 
lamivudine (3TC)/zidovudine (ZDV), 
didanosine/tenofovir  (DDI/TDF), poor adherence, 
advanced age, and being ARV naïve (63). The factors, 
which contribute  VL-/CD4+ include sexual transmission 
of HIV, absence of clinical progression, lower baseline 
CD4 counts, higher baseline VL, low-level viral rebound 
during the first year after achieving undetectable VL,   
younger age, pretreatment and saquinavir regimen (63), 
use of 3TC/ZDV, ddI/3TC, or ddI/stavudine, ritonavir-
boosted protease inhibitor-(PI) based regimen (36, 64), 
and treatment compliance (53). 
 
Evidences showed that the frequency and risk factors for 
discordant responses to HAART in developing and 
developed countries were comparable (64). However, the 
studies are different in terms of study design, 
inclusion/exclusion criteria, ethnicity, ART experience, 
sample size, ARV regimen, length of follow-up, and the 
definitions, which results in the variations of results 
related to the factors associated with discordant 
responses.  Therefore, longer follow-up studies are highly 
pertinent to assess the pattern as well as the long-term 
impact of concordant/discordant responses treatment 
outcomes and the risk factors associated with in the 
context of local settings (64). 
 
HAART and TB/HIV co-infection 
Co-infection with TB/HIV complicates pathogenesis, 
epidemiology, clinical presentation, diagnosis, treatment, 
prevention aspects of one or the other. Whereas 11% of 
all HIV/AIDS -related adult mortality are attributed to 
TB, 39% of all TB related deaths are attributable to HIV 
(64). 
 
Patients from TB endemic areas present themselves to 
the health facilities for TB/HIV diagnosis and 
simultaneous treatment. Even though the optimal interval 
between starting TB treatment and ART remains to be 
determined (65), the objectives for initiating early ART 
in patients on anti-TB treatment are to reduce the risk of 
HIV related morbidity/mortality and improved sputum 
smear conversion; while the factors for differing ART 
includes high pill burden, poor adherence, impaired 
tolerability, drug with-drug interactions, toxicity, and 
morbidity and mortality because of TBIRIS (66). 
 
According to WHO guidelines (21), ART should be 
initiated within 2 to 8 weeks of anti-TB treatment in 
those with CD4+ count < 200 cells/ul; in the continuation 
phase of anti-TB treatment in those with CD4+ cell 
counts 200-350 cells/ul; but with great urgency in those 
highly immunocompromised patients. However, in cases 
a person needs TB and HIV treatment concurrently, first 
line treatment options include ZDV/3TC or d4T/3TC 
plus either an NNRTI or ABC (5). 
 
Overall, HAART restores host immune response specific 
to Mycobacterium tuberculosis (MTB), reduces incidence 
of TB, and improves survival, while anti-TB treatment in 
TB/HIV co-infected patients on the other hand minimizes 
the negative effects of TB on the course of HIV and 
reduces the transmission of MTB (59, 67, 68, 69). 
 
Whereas the long- term impact of HAART on TB control 
is dependent, in part, on the rate and extent of MTB 
specific immune restoration (68), TB disease prevalence 
at baseline, and incidence rate during the initial months 
of ART are higher on those enrolled for ART, which 
results in higher morbidity, mortality and complicates the 
delivery of ART (Fig 1) (68, 70, 71). 
 
Specific strategy is therefore required to reduce the 
impact of TB in the era of ART.WHO has recommended 
the ‘3Is’ strategy that incorporates intensified case 
finding, infection control and isoniazed preventive 
therapy to reduce the burden of TB in people living with 
HIV (72). However, the scenario of intensive case 
finding is also greatly affected by the screening strategy 
applied, immunodeficiency and the diagnostic tests 
available (64). In this regard, the fact that most diseases 
are sputum smear negative and culture-positive (73) is 
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Figure 1: The incidence of TB in HIV infected patients on HAART relative to duration of HAART (days) and CD4+ 
counts (***: CD4+ < 50; **: CD4+ 51-100; *: CD4+ 101-200  
(adapted from 63) 
 
Furthermore, whereas concurrent treatments with anti-TB 
and HAART improves survival of the patients (74), there 
are also reported complications during the dual treatment 
including drug interactions, increased risk of treatment 
interruptions, high pill burden, shared toxicities, and 
paradoxical TB Induced Reconstitution Inflammatory 
Syndrome (TBIRIS) (65,75). Nevirapine concentrations 
are frequently sub-therapeutic in patients on rifampicin-
based TB treatment, which may result in inferior 
virological outcomes (65), while others have reported 
virological responses in TB/HIV patients to be similar 
with those who did not have TB (70). 
 
Discussion 
This review has summarized the success of HAART at 
national and continental level on one hand, but also the 
major challenges observed related to the parameters 
which have been implemented to monitor the patients on 
HAART. The key questions addressed in this review, 
therefore, includes: the profile of immunologic and 
virologic responses to HAART, immunologic and 
virologic failures and the factors associated with; 
Discordant/Concordant immunovirologic responses,   
with special emphasis to the potential limitations of 
applying clinical and immunologic parameters for 
monitoring of patients on HAART in resource limited 
settings like in Ethiopia. 
 
Immunologic responses to HAART 
Overall, CD4+ recovery post-HAART occurs in two 
phases: in the first phase of the two months, rapid 
recovery of the CD4+ cells took place mainly due to the 
release of the sequestered cells in the body tissue; 
whereas from the third month onwards (the second 
phase), the rate of CD4+ recovery is slow and the factors 
contributed for the increase in cell number includes re-
generating of new cells from bone marrow, and reduction 
of programmed cell death (37, 38).
Moreover, although the rate of CD4+ recovery depends 
on several factors including baseline CD4+ count, control 
of viral replication overtime, the stage of the disease at 
baseline, duration on treatment (17, 40), the time required 
for CD4+ cells to reach the normal values ranges from 
two to eight years  (24, 41). However, the fact that there 
is significant reduction in the frequency of OIs, and in 
morbidity and mortality, irrespective of the slow 
recovery rate as well as low absolute number of CD4+ 
cells post-HAART, raises a research question “how 
strong is the restoration of the functional immune 
response specific to variety of OIs post-HAART 
irrespective the low number of CD4+ cells in the 
periphery?” 
 
Moreover, based on the observation that  absent or 
modest improvements in CD4+ response occurs in 5–
27%  of the patients on HAART (42,43,44),  where the 
risk factors included  rate of CD4+ and VL decline, (47), 
old age (17, 47), co-infection, medications, immune 
activation (17), and apoptosis (50), there are two major 
un-resolved challenges remained: a) absence of clear 
understanding on how to assess immunologic failures 
with regard to the duration of time after HAART 
initiation, and the clinical risks as well as the possible 
treatment for immunological failures (46); and b) absence 
of defined cut-off values to determine immunologic 
failures. 
 
Furthermore, whereas clinical and immunological 
parameters are recommended as a proxy for VL test to 
evaluate the response of HAART for resource poor 
settings (21), the occurrence of higher morbidity, 
mortality and complex profile of resistance in settings 
where VL testing is not available (31), which could be 
due to the poor sensitivity (20%-33%), and specificity 
(86%-90%), of immunologic markers to identify 
virologic failures (29, 30), implies the timely need to 
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incorporate VL testing to confirm treatment failures, in 
settings like in Ethiopia where free access to ART is 
expanded. 
 
Virologic responses to HAART  
Whereas CD4+ count, but not VL test (21), is the best 
biomarker for initiation ART (5), VL measurement is a 
golden standard to monitor patients on ART (51). 
However, higher cost, the need of trained human 
resource and infrastructure remains to be the major 
obstacle for the resource limited settings to implement 
VL test, indicating the need of simple and cheap point of 
care (POC) VL assay for poor countries. Overall, 
although virologic success observed in 75-90.7% of the 
patients by 12 month on HAART, a decrease in the 
proportion of those with successful virologic response, 
and an increase in viral rebound, as the time on HAART 
increased, has been reported  (54,55).   Moreover, the 
absence of defined cut-off values for virologic failure, 
like that in immunological failure, remains to be a major 
challenge when applying VL test for patient monitoring.  
 
Discordant/Concordant immunovirologic responses to 
HAART 
Despite the independent immunologic and virologic 
failures post-HAART, discordant immunovirologic 
responses (VL+/CD4- , VL-/CD4+)  which is known to be 
associated with higher risk of clinical progression and 
mortality (62,63), and causes more challenges to the 
health care providers during patient management and 
monitoring (51), is another significant challenge during 
the monitoring of patients on HAART. Therefore, 
whereas the mechanisms of discordant immunovirologic 
responses are not fully understood (36), local follow-up 
studies are highly pertinent to assess the magnitude and 
long-term effect, as well as the risk factors associated 
with discordant immunovirologic responses      
 
HAART and TB/HIV co-infection 
Whereas TB is the most common OI in HIV patients 
(64), the summary of the literatures in this review have 
shown HAART restores the host immune response 
specific to TB, reduces incidence of TB, morbidity and 
mortality related to TB (68, 69). However, time to start 
ART, higher incidence of TB in HIV positive on 
HAART than that of HIV negatives (indicated 
incomplete immune restoration specific to TB), 
toxicities, TBIRIS, and drug interactions,  has been 
reported as major obstacles  (65,75). 
   
Therefore, in TB/HIV clinics where simultaneous 
treatment with anti-TB and ART are provided, awareness 
of the health professionals is highly essential for the 
comprehensive and effective management of the TB/HIV 
patients.  Furthermore, future researches aimed to address 
better treatment strategies of TB/HIV patients, the 
evolution of immune restoration specific to TB, and 
TBIRIS, are highly relevant. 
 
Summary 
HAART restores host immune responses, decreases risk 
of OI, morbidity and mortality globally. The un-resolved 
questions related to HAART have to do with variations in 
the treatment outcomes (countries, Ethnic), cut-off values 
for immunovirological failures, discordant results; drug 
resistance, toxicity, drug interactions, and early mortality. 
 
Since clinical and immunological assessments lack 
sensitivity/specificity to diagnose virologic failures, 
complications in the patient monitoring in the  extensive 
ART expansion that might occur in the resource poor 
settings, where patient monitoring is dependent on 
clinico-immunological parameters. Incorporating VL 
testing to confirm treatment failures, as well as 
genotyping testing for treatment failed samples, if not 
pre-HAART resistance testing, should be part of the 
immediate plan.  Furthermore, considering the rapid 
expansion of ART where the long-term effect of which is 
not well investigated, and the research data on ART are 
predominantly from the developed world, local research 
data from well defined cohorts of patients on long-term 
HAART, which can complement data from randomized 
clinical trials (76) are highly pertinent and timely. 
Likewise, routine national surveys for transmitted and 
acquired ARV drug resistance and early warning 
indicators (EWI) should also be implemented in parallel 
to the speeded up expansion of ART. 
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